A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

ReclutandoFase 2ClinicalTrials.gov

ID: NCT07215312Tipo: INTERVENTIONALInicio: 13 de oct de 2025Fin estimado: 1 de dic de 2026

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 70 YearsSexo: ALL

Criterios de inclusión

Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
Have type 2 diabetes
Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)

Criterios de exclusión

Have type 1 diabetes

Intervenciones

drug

LY3938577

Administered SC

drug

Degludec

Administered SC

Ubicaciones

CIPREC

Buenos Aires, Argentina

RECRUITING

Mautalen Salud e Investigación

Buenos Aires, Argentina

RECRUITING

Consultorio de Investigación Clínica EMO SRL

Buenos Aires, Argentina

RECRUITING

Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

Buenos Aires, Argentina

RECRUITING

Instituto Centenario

CABA, Argentina

RECRUITING

Instituto Médico Catamarca IMEC

Rosario, Argentina

RECRUITING

Patrocinadores

PrincipalEli Lilly and Company

Contactos

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

LillyTrials@Lilly.com 317-615-4559

Physicians interested in becoming principal investigators please contact

CONTACT

clinical_inquiry_hub@lilly.com

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 2, Randomized, Open-Label, Comparator-Controlled ... | EligiMed